10-Q: Qualigen Therapeutics Faces Severe Liquidity Crisis Amidst Rising Losses and R&D Slowdown

Qualigen Therapeutics, Inc. reported a significant increase in net loss and a drastic reduction in cash reserves for Q1 2025, raising substantial doubt about its ability to continue as a going concern, despite ongoing efforts to raise capital.

Summary

• Net loss increased to $2.65 million for the three months ended March 31, 2025, up from $2.03 million for the same period in 2024.
• Cash and cash equivalents plummeted to $30,210 as of March 31, 2025, a significant decrease from $1,174,608 at December 31, 2024.
• Total current liabilities rose to $2.81 million as of March 31, 2025, from $2.01 million at December 31, 2024, primarily due to new promissory notes.
• General and administrative expenses surged by 135% to $2.49 million for Q1 2025, largely driven by $1.4 million in investor relations costs.
• Research and development expenses were cut by 90% to $33,167 for Q1 2025, reflecting a significant slowdown in therapeutic product development due to financial constraints.
• A new credit loss expense of $197,000 was recorded on short-term notes receivable from Marizyme, indicating concerns about collectibility.
• Substantial doubt exists about the company's ability to continue as a going concern for the one-year period following the financial statement issuance date.
• The company is in arrears on accounts payable to important partners.
• A lawsuit was filed by LifeSci Capital LLC on January 29, 2025, for $503,483 in alleged unpaid fees related to common stock offerings.
• Material weaknesses in internal control over financial reporting persist due to insufficient personnel, ineffective IT General Controls, and lack of formalized documentation.

Sentiment

Score: 2

Explanation: The company faces severe liquidity issues, evidenced by critically low cash reserves, increasing losses, and a significant slowdown in core R&D activities. The explicit 'going concern' doubt, arrears on payables, and reliance on high-penalty short-term debt indicate a highly distressed financial state, despite ongoing capital raising efforts.

Positives

• Successfully filed the 2024 Form 10-K by June 30, 2025, and the 2025 Q1 Form 10-Q by July 18, 2025, which allowed for continued listing on The Nasdaq Capital Market.
• Secured $3,515,000 in short-term borrowings from nine investors between January and June 2025.
• Plans to close a private placement transaction in July 2025 to raise additional equity funding, expected to provide liquidity through calendar year-end.
• Implemented dramatic expense controls in an effort to stem the rate of losses.
• Interest income increased to $0.1 million for Q1 2025 from $2,000 in Q1 2024, primarily from recording interest on Marizyme notes receivable.

Negatives

• Cash and cash equivalents decreased significantly to $30,210 as of March 31, 2025, from $1,174,608 at December 31, 2024.
• Net loss increased to $2.65 million for the three months ended March 31, 2025, compared to $2.03 million for the same period in 2024.
• Accumulated deficit grew to $125.7 million as of March 31, 2025.
• Used $1.6 million in cash from operating activities in Q1 2025, an increase from $0.78 million in Q1 2024.
• General and administrative expenses increased by 135% due to high investor relations costs ($1.4 million).
• Research and development activities were significantly slowed down (90% decrease in expense) due to financial constraints.
• A $197,000 credit loss expense was recorded on the short-term note receivable from Marizyme, indicating concerns about collectibility.
• The company is in arrears on accounts payable to important partners.
• New short-term promissory notes totaling $0.8 million were issued in Q1 2025, with a potential $0.3 million penalty in case of default.
• Subsequent to Q1, additional short-term borrowings of $225,000 (with $0.8 million penalty provision) and $2.3 million were incurred, further increasing debt.
• The company faces a lawsuit from LifeSci Capital LLC for $503,483 in alleged unpaid fees.
• Material weaknesses in internal control over financial reporting persist and are not expected to be remediated without additional funding.

Risks

• Substantial doubt exists about the ability to continue as a going concern for the next year due to recurring losses and negative cash flow.
• Inability to procure sufficient working capital to continue and complete the development, testing, and launch of prospective drug products.
• Uncertainty regarding the ability to successfully develop and commercialize any drugs, including QN-302 and Pan-RAS.
• Challenges in progressing drug candidates through preclinical and clinical development and obtaining requisite regulatory approvals.
• No assurance that future clinical trial data will be favorable or confirm improvements over other products.
• Inability to obtain further financing on favorable terms, or at all, which could lead to delays, reductions, or elimination of R&D programs and commercialization efforts.
• Dilution of common stockholders' ownership interests if additional capital is raised through equity or convertible debt sales.
• Debt financing, if available, may involve agreements that include covenants limiting specific actions like incurring additional debt or declaring dividends.
• Relinquishing valuable rights to technologies, future revenue streams, or product candidates if funds are raised through third-party funding or collaborations.
• Adverse effects on the company's minority interest in NanoSynex due to ongoing wars in Ukraine and Israel, and political instability in the Middle East.
• Impact of global economic conditions, inflation, slowing growth, and rising interest rates on the company's business.
• Material weaknesses in internal control over financial reporting due to insufficient accounting personnel, ineffective IT General Controls, and lack of formalized documentation, which may not be remediated without additional funding.
• Potential for actual credit losses on Marizyme Notes to differ materially from current estimates due to the inherently uncertain nature of the debtor's financial condition.
• Risk of significant variability in future financial statements due to mark-to-market valuation of liability-classified warrants based on changes in the public market common stock price.

Future Outlook

The company expects to continue to incur net losses and negative cash flow from operations, which will challenge its liquidity. Management is strategically reviewing plans to advance its therapeutics pipeline and will ramp up development when properly funded through either capital markets or strategic partnerships. The company plans to close a private placement transaction in July 2025 to raise additional equity funds, which are expected to provide liquidity through calendar year-end.

Management Comments

• "Management and the board are strategically reviewing plans on how to best advance our therapeutics pipeline, and will ramp up development when properly funded through either capital markets or strategic partnerships."
• "Given our financial situation, the company slowed the development of the QN-302 Phase 1 Study beginning in the second quarter of 2024."
• "We have also implemented dramatic expense controls in an effort to stem the rate of losses."
• "The Company deemed this expense [investor relations] necessary to raise additional funding which would provide liquidity to the Company for business operations. This expense is not anticipated to be recurring in future periods."
• "We lack the resources to employ additional personnel to help mitigate these material weaknesses and we foresee that these material weaknesses will not be remediated until we receive additional funding to support our accounting department."

Industry Context

Qualigen Therapeutics operates in the highly capital-intensive and high-risk early-clinical-stage biotechnology sector, specifically focusing on oncology. The significant reduction in R&D spending and reliance on short-term debt and planned equity raises are indicative of the funding challenges often faced by small biotech companies without commercialized products. The ongoing global economic conditions and geopolitical conflicts are noted as potential adverse factors, reflecting broader industry concerns about inflation, supply chains, and market stability. The company's strategy to slow development until better funding is secured is a common response in this industry when faced with liquidity constraints, contrasting with larger, more established pharmaceutical companies that can sustain R&D through diverse revenue streams.

Comparison to Industry Standards

• The company's accumulated deficit of $125.7 million and recurring net losses are typical for early-stage biotechnology companies that are pre-revenue and heavily invested in research and development, similar to many small-cap oncology biotechs like Oncternal Therapeutics (ONCT) or Kura Oncology (KURA) in their early phases, which also experience significant cash burn before potential product commercialization.
• The drastic reduction in R&D expenses by 90% to $33,167 in Q1 2025 is a severe measure, indicating a near halt in core drug development activities. This contrasts sharply with industry peers that typically maintain consistent or increasing R&D investment to advance their pipelines, even during challenging periods, often through non-dilutive partnerships or larger capital raises.
• The reliance on short-term promissory notes with high potential penalties and the continuous need for capital raises (including a planned July 2025 private placement) highlights a precarious financial position, more akin to distressed micro-cap biotechs struggling for survival rather than those with robust funding pathways like larger clinical-stage companies such as Mirati Therapeutics (MRTX) or Seagen (SGEN) (prior to acquisition).
• The identified material weaknesses in internal controls, particularly the lack of sufficient accounting personnel and ITGC, are significant governance issues that are not standard for publicly traded companies, regardless of size, and could raise concerns for institutional investors regarding financial reporting reliability.
• The co-development agreement with Marizyme for DuraGraft, a vascular conduit solution, represents a diversification outside of core oncology therapeutics, which is unusual for a company explicitly stating its focus on cancer treatments. This could be seen as a short-term revenue generation attempt, but its impact on the overall oncology pipeline remains unclear and is not a standard strategic pivot for a focused biotech.

Corporate Governance

Legal Proceedings

• On January 29, 2025, the Company was named as a defendant in an action brought by LifeSci Capital LLC (LifeSci) in the U.S. District Court for the Southern District of New York, alleging failure to pay $503,483 in connection with common stock offerings.
• The Company filed its answer on March 17, 2025, denying material allegations and asserting affirmative defenses, vigorously defending the lawsuit.
• As of May 29, 2025, the matter is in the discovery phase, and the Company does not believe a loss is probable or reasonably estimable.

Related Party Transactions

• Company issued an 8% Senior Convertible Debenture for $3,300,000 to Alpha Capital Anstalt (Alpha) on December 22, 2022, which was fully converted into common stock during 2024.
• Company issued an 8% Convertible Debenture (2024 Alpha Debenture) for $550,000 to Alpha on February 27, 2024, which was repaid in cash on November 20, 2024.
• Company issued an 8% Convertible Debenture (2024 Chen Debenture) for $1,100,000 to Yi Hua Chen (assigned from Alpha) on April 12, 2024, which was settled by conversion into Series A-2 Preferred Stock on November 18, 2024.
• Company issued warrants to Alpha for common stock on May 22, 2020 (141 shares outstanding as of March 31, 2025, exercisable until May 22, 2025).
• Company issued a warrant to Alpha to purchase 50,000 shares of common stock on December 22, 2022 (18,002 shares outstanding as of March 31, 2025, exercisable until June 22, 2028).
• Company issued a warrant to Alpha to purchase 18,001 shares of common stock on February 27, 2024 (all outstanding as of March 31, 2025, exercisable until February 27, 2029).
• Company issued a liability classified warrant to Chen to purchase 36,001 shares of common stock on April 12, 2024 (reclassified to equity after shareholder approval on October 25, 2024).
• Co-Development Agreement with Marizyme, Inc. (Marizyme) entered on April 11, 2024, involving funding payments and potential royalties on DuraGraft sales.
• Advanced $2,562,400 to Marizyme as of March 31, 2025, via demand promissory notes (Marizyme Notes) bearing 18% interest, with a $557,000 allowance for credit losses.
• Subsequent to March 31, 2025, an additional $1,213,500 was advanced to Marizyme (April-July 2025) via demand promissory notes.
• In April 2025, the company received $220,000 (less $20,000 legal fees) from Alpha Capital Anstalt for a convertible promissory note.

Stakeholder Impact

• Shareholders: Significant dilution risk from ongoing and planned equity capital raises; potential for further stock price volatility due to severe liquidity issues, increased losses, and Nasdaq delisting concerns (though temporarily resolved); rights of common stockholders may be adversely affected by liquidation preferences of preferred stock.
• Employees: Potential impact on job security and morale due to financial distress, significant slowdown in R&D activities, and expense controls.
• Creditors: Increased risk of non-payment, as evidenced by the company being in arrears on accounts payable and the inclusion of penalty provisions on new short-term notes due to default risk.
• Partners (e.g., Marizyme, UCL Business Limited, ULRF): Risk to ongoing collaborations and funding, as R&D has been slowed and credit losses recorded on notes receivable from Marizyme; company is in arrears on accounts payable to important partners.
• Regulatory Authorities (SEC, Nasdaq): Continued scrutiny due to financial reporting delays and material weaknesses in internal controls.

Next Steps

• Ramp up therapeutic product development when properly funded through capital markets or strategic partnerships.
• Continue to monitor relevant events and conditions and update assumptions and allowance for credit losses on Marizyme Notes.
• Continue to defend the lawsuit brought by LifeSci Capital LLC.
• Remediate material weaknesses in internal control over financial reporting once additional funding is secured for the accounting department.
• Close a private placement transaction in July 2025 to raise additional equity funds.

Key Dates

Recommendation

Keywords

Qualigen Therapeutics, QLGN, SEC Filing, 10-Q, Quarterly Report, Biotechnology, Oncology, Cancer Treatment, QN-302, Pan-RAS, Drug Development, Clinical Trials, Preclinical, Liquidity, Going Concern, Financial Results, Net Loss, Cash Flow, Capital Raise, Convertible Debt, Warrants, Marizyme, DuraGraft, SEC Compliance, Internal Controls, Risk Factors, Nasdaq Delisting, Pharmaceuticals